Ireland
--:--IST
Latest
Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns Project Management Failures: Lessons for Healthcare FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli WeBuild Programme: 50+ Women-Led Ventures and How to Apply Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns Project Management Failures: Lessons for Healthcare FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli WeBuild Programme: 50+ Women-Led Ventures and How to Apply Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing
Clinical Trials in Portugal / NCT05735730
Active, not recruiting Not applicable

Can the Risk for AMD be Modulated?

NCT05735730 · tracked via the Priya Life Science Portugal tracker
Sponsor
Association for Innovation and Biomedical Research on Light and Image
Phase
Not applicable
Started
2023-06-26
Last updated
2025-09-23

Condition(s) studied

Age-Related Macular Degeneration (ARMD)

Investigational drug(s) / intervention(s)

Blood draw

Blood draw: The study intervention consists of a blood draw for genetic analysis.

Study summary

The goal of this Cross-sectional, interventional study is to learn about whether different risk factors, as Mediterranean diet, lifestyle and concomitant medication can modulate the risk imprinted by genetics in Age-related macular degeneration (AMD). The main question it aims to answer is: How the genetic risk interacts with environmental and lifestyle factors, especially Mediterranean diet and chronic medication, in order to assess how this interplay protects or presents higher risk for the establishment or the progression of AMD.

Participants:

Vital Signs will be measured; Medical History, Demographics, Nutritional/lifestyle habits and Family History of AMD will be recorded; Ophthalmological Examination will be performed Genetic analysis will be performed.

Eligibility

Sex
ALL
Min age
55 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult subjects residing in the Lousã region who participated in the epidemiologic study; * Subjects capable of understanding the information about the study and to give their written informed consent to enter the study; * Subjects willing and able to comply with the study procedures. Exclusion Criteria: \- No exclusion criteria apply.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
AIBILI-CEC (AIBILI- Clinical Trials Centre) Coimbra Portugal

More Association for Innovation and Biomedical Research on Light and Image trials in Portugal

Prediction of Progression of Retinal Ischemia in Diabetes Active, not recruiting
Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO) Recruiting
Analysis of DR Progression to Identify Risks and Need for Treatment Recruiting
Home Monitoring in eAMD Treatment Starting soon
Characterization of Potential Biomarkers of Eye Disease and Vision Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05735730 on ClinicalTrials.gov ↗ ← All trials in Portugal